Daniel Barenboim reveals he has Parkinson's disease
In a statement shared via his Berlin-based foundation, 82-year-old Barenboim said that he had been "very touched by the support I have received over the last three years".
In October 2022, Barenboim said he was dropping some of his performing activities after he was diagnosed with a "serious neurological condition" and in January 2023 announced he was stepping down as general musical director of Berlin's State Opera.
"I would like to share today that I have Parkinson's Disease," Barenboim said in Thursday's statement, adding that he was "planning to maintain as many of my professional commitments as possible".
"If I am unable to perform, it is because my health does not allow me to."
Barenboim said his most important responsibility was the West-Eastern Divan Orchestra, a project he founded in 1999 with the late Palestinian-American writer and intellectual Edward Said to encourage rapprochement between young Israeli and Arab musicians.
He said that he would "continue to conduct the Divan whenever my health allows" but wanted to ensure "the Divan has the opportunity of working with other excellent conductors going forward".
Barenboim has been acclaimed for a stellar career which saw him begin performing internationally as a pianist aged 10 and then become a leading conductor.
The son of Jewish piano teachers has also been an outspoken campaigner for peace in the Middle East.
jsk/sr/phz
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
an hour ago
- The Hill
Repealing EPA's endangerment finding will cause a public health nightmare
As America faces increasing health threats from wildfire smoke, summer heat waves and rising cases of asthma and other respiratory illnesses, the last thing we need is to reverse laws that protect U.S. air quality. Yet, that's precisely what the Trump administration intends to do by proposing a repeal of a central scientific finding that serves as the basis for the Clean Air Act — legislation that has saved millions of American lives and been responsible for monumental advancements both to our environment and public health. U.S. Environmental Protection Agency Administrator Lee Zeldin announced last month the agency plans to end a long-held 'endangerment finding' that asserts carbon dioxide and other greenhouse gases present a risk to human health. If that happens, it will neutralize the federal government's ability to combat climate change and enforce laws intended to protect America's wellbeing. One of those laws is the Clean Air Act. Enacted in 1970, it has been one of the most successful public health policies in U.S. history. It's credited with reducing six of the most common air pollutants in the U.S. by nearly 80 percent while saving over 230,000 early deaths and avoiding over 120,000 emergency room visits every year. It has reduced chronic bronchitis, infant mortality and prevented millions of cases of asthma exacerbation as well. These statistics aren't conjecture: They're sourced directly from the EPA's own website, the same agency now leading the charge to turn the clock back on these remarkable achievements. Zeldin's announcement claims that the reversal of the endangerment finding will 'undo the underpinning of $1 trillion in costly regulations.' But the positive U.S. economic impact from the Clean Air Act alone far exceeds this figure. By reducing hospital visits, sick days and treatment of costly respiratory-related disease, the EPA estimates the Clean Air Act has created $2 trillion in U.S. economic benefit as of 2020 — twice the amount Zeldin asserts the endangerment finding's repeal would create. Further, clean energy has proven itself to be a source of strong job creation. The Department of Energy found that jobs in renewable energy grew more than twice as fast as the vibrant 2023 U.S labor market. And the science couldn't be clearer: Clean air is critical to public health. 'Decades of research have shown that air pollutants such as ozone and particulate matter increase the amount and seriousness of lung and heart disease and other health problems,' the EPA states. Worse, those pollutants are disproportionately burdened by communities of color. A 2024 Milken Institute of Public Health study found that marginalized communities have eight times the number of pediatric asthma cases and a 30 percent higher chance of dying early from pollution exposure. That same study attributed this inequality to the close proximity many minority communities share with industrial manufacturing facilities. Imagine what those numbers would be if the endangerment finding is reversed and the U.S. can no longer enforce Clean Air Act provisions. Zeldin referred to the EPA action as 'driving a dagger into the heart of the climate change religion,' and that it would be 'the largest deregulatory action in the history of America.' But doing so will only cause greater sickness in America and inundate an already stressed U.S. health care system. Increased exposure to air pollution will result in higher numbers of emergency room visits, increased rates of chronic illness and heightened health care costs. The medical and environmental advocacy community agree greater exposure to carbon dioxide and greenhouse gas is a bad idea. Groups such as the American Lung Association, American Public Health Association, American Thoracic Society, World Wildlife Fund, along with nursing organizations and medical societies all stand in strong opposition to the EPA's proposed action. Zeldin's proposal follows another questionable deregulatory move by the EPA in recent weeks to reintroduce dicamba, a weed killer used on soybeans and cotton. Use of the pesticide was halted by a federal court last year. A 2020 study in the International Journal of Epidemiology found that exposure to dicamba was reportedly 'linked to some cancers, including liver cancer and a type of leukemia affecting the blood and bone marrow.' But the EPA has argued it 'has not identified any human health or dietary risks of concern.' The U.S. government's job is to protect America's citizens. The Clean Air Act has saved millions of lives, safeguarded our skies and proven that environmental laws and economic progress can peacefully coexist. Repealing the endangerment finding will set America on a dangerous path and put the health and welfare of every American at risk.
Newsweek
an hour ago
- Newsweek
Pet Owners Issued Drinking Water Warning
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Dogs could be the first to show signs of dangerous water contamination in American homes relying on private wells, a veterinary professor has told Newsweek. "We tested the drinking water from the homes of dog owners who rely on private wells and found that every sample contained detectable minerals or metals—some at levels above health-based guidelines set by the EPA [Environmental Protection Agency]," veterinary informatics professor at Virginia Tech, Audrey Ruple, told Newsweek. "Since dogs often drink from the same water sources as their human families, they may be the first to show signs of long-term exposure to contaminants like lead or arsenic," she continued. "This makes them important early warning systems—or sentinels—for environmental risks that people are also exposed to." Ruple recently co-authored a study with other researchers from Virginia Tech and the University of Washington, which found that the majority of sampled well water contained excessive levels of heavy metals, raising health concerns for both pets and their human families. Why It Matters Roughly 15 million U.S. households rely on private wells, which fall outside of EPA oversight and are not subject to federal testing regulations. The study highlights that these homeowners may be unaware of health risks lurking in their drinking water, especially for pets that often consume more water per pound of body weight than humans. What To Know Marc Edwards, a distinguished professor of civil and environmental engineering at Virginia Tech, said in an interview with Newsweek: "The lead and copper source is almost always the plumbing infrastructure, whereas arsenic and other constituents are often naturally occurring in the ground water. Consumers can often have their water tested through college extension programs, or by contacting local water testing laboratories. There are filters or treatment devices that can remove every type of contaminant." Published in PLOS Water and conducted across 10 U.S. states, the research found elevated levels of toxic metals in two-thirds of homes tested. According to SciTechDaily, 13 of the homes exceeded EPA health guidance levels for arsenic, lead, or copper. The findings suggest that dogs are exposed to similar environmental hazards as humans, yet their quicker metabolisms and shorter life spans may reveal symptoms earlier. Environmental conditions influenced contamination levels. Researchers noted that homes near fracking sites showed higher sodium and sulfur levels, while proximity to railroads correlated with increased manganese. According to DVM360, water treated using reverse osmosis showed the lowest health risks to dogs. The study analyzed water samples from 178 dogs enrolled in the Dog Aging Project, a national health study. Researchers discovered that 64 percent of private well samples exceeded health guidelines for at least one heavy metal, including arsenic, lead, or copper. All 178 samples contained detectable levels of at least some of 28 different metals tested. Co-author Leigh-Anne Krometis, associate professor of biological systems engineering at Virginia Tech, stressed to Newsweek that "this study examined private well water samples." "These are all maintained by individual homeowners and not subject to federal regulations on testing, treatment, etc. So these were not 'city' water samples," he said. File photo of a dog drinking water, taken in Saxony-Anhalt, Wernigerode, taken in August 2022. File photo of a dog drinking water, taken in Saxony-Anhalt, Wernigerode, taken in August 2022. AP What People Are Saying Co-author Leigh-Anne Krometis said: "In this small study, 59 percent of the samples returned had more than 20 ppm sodium... Salt sometimes is actually high in well water because of the presence of a treatment system that relies on ion exchange to remove nuisance elements like iron and manganese. So it's not that the groundwater is 'polluted' per se, it's actually a management decision to make water more palatable." Co-author Audrey Ruple said: "If their household uses a private well, a practical action they can take is to have their water tested through a certified lab that can check for metals like lead, arsenic, and copper. Testing is relatively inexpensive and easy to do. If contaminants are detected, installing a treatment or filtration system can reduce the risk of negative health impacts." What Happens Next The researchers plan to expand their work by analyzing the long-term health outcomes in dogs exposed to heavy metals. They believe that identifying links between environmental contamination and chronic conditions could improve both veterinary care and public health guidance. Until then, they stress annual water testing as a simple but essential step for well owners. Krometis told Newsweek: "Water is a utility we often take for granted, and many (if not most) private well owners do not realize that it is their sole responsibility to manage their system. Testing is the first step to understand whether there are things in the water that might pose a risk to themselves and their family members, furry or otherwise."
Business Wire
an hour ago
- Business Wire
ClearStrand-ASD, First-of-Its-Kind Autism Screening Tool, Now Available in Japan
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- LinusBio, a leader in precision exposome medicine, announced today that ClearStrand-ASD™, its biochemical autism screening test, is now available to patients and providers in Japan for research use through its partnership with YAC Bio. This milestone marks LinusBio's first international expansion and represents a significant step in the company's mission to enable earlier identification of autism spectrum disorder (ASD) globally. Today marks a transformational moment in our mission to make early autism screening accessible worldwide. Share ClearStrand-ASD requires only a strand of hair to detect molecular signatures associated with autism spectrum disorder. This innovative, non-invasive approach provides healthcare providers with an objective screening method that can help identify ASD risk as early as one month of age, allowing families to pursue intervention during the most crucial period of early development. "Today marks a transformational moment in our mission to make early autism screening accessible worldwide," said Dr. Manish Arora, Founder and CEO of LinusBio. "Japan represents our first step beyond U.S. borders, and we chose this market because of its sophisticated healthcare infrastructure and commitment to pediatric developmental care. Japanese families dealing with autism concerns will now have access to the same cutting-edge screening technology that has already helped multiple American families get answers earlier than ever before." The Japanese launch builds on ClearStrand-ASD's successful rollout across the United States, where it is now available in 49 states. YAC Bio will partner with hospital systems in Japan to facilitate the implementation of this first-of-its-kind biomarker test for autism. LinusBio's expansion into Japan is facilitated through its existing partnership with YAC Bio (part of Y.A.C. Holdings), the Japanese multinational that invested over 1 billion yen in the company. Beyond providing market access, Y.A.C. Holdings contributes manufacturing expertise and automation capabilities that support LinusBio's scaling efforts globally. "By combining the world's only hair-cutting robotics technology with the innovative hair exposome analysis developed by LinusBio in the United States, we have contributed to the development of the world's first biomarker screening test for autism spectrum disorder. Following its launch in the U.S., we are now offering this test in Japan through our group company, YAC Bio," said Takefumi Momose, President and CEO, Y.A.C. Holdings Co., Ltd. "We sincerely hope that this test will support individuals, families, and communities in Japan who are concerned about autism." The Japan availability of ClearStrand-ASD represents the first phase of LinusBio's international expansion strategy, with the company evaluating additional markets where ClearStrand-ASD could address unmet needs in early autism detection. About ClearStrand-ASD ClearStrand-ASD is a biochemical test intended to help health care providers rule out autism spectrum disorder (ASD) in children 1 to 48 months. The test analyzes a strand of hair to map the dynamic patterns of an individual's unique biological responses at a molecular level to environmental exposures over time and uses an algorithm to assess the likelihood of autism. It is not a genetic test and must be ordered by a licensed health care provider (Rx only). ClearStrand-ASD is performed at LinusBio's CLIA-certified laboratory (CLIA #31d2307499). For more information visit: About LinusBio LinusBio (Linus Biotechnology Inc.) is a patient-centric, breakthrough science precision exposome medicine company headquartered in New Jersey. The Company's program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology. LinusBio is actively exploring additional international partnerships to expand global access to its innovative diagnostic solutions. For more information, visit About Y.A.C. Holdings Y.A.C. Holdings is a Japan-based company specializing in developing, designing, and manufacturing mechatronics-related products. The company collaborates with LinusBio on hardware innovations to scale testing capacity, driving breakthroughs in robotics and laboratory automation.
